Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
Status
Hovedstatus
Detaljstatus 		I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP2817299
Europeisk (EP) publiserings nummer EP2817299
EP levert
EP søknadsnummer 13712928.4
EP meddelt
Prioritet 2012.02.24, IN KO01782012, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Lupin Limited (IN)
Oppfinner SHUKLA, Manojkumar, Ramprasad (IN) .... se mer/flere nedenfor
Fullmektig BRYN AARFLOT AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Patentkrav1. En forbindelse med formel (V):eller dens farmasøytisk akseptable salt derav, hvorR1 er valgt fra halogen, substituert eller usubstituert alkyl, haloalkyl, sykloalkyl, cyano, -C(O)alkyl og -OR6 hvor R6 er hydrogen eller alkyl; 'q' er 0, 1, eller 2; R2 er substituert eller usubstituert fenyl eller substituert eller usubstituert naftyl hvor substituentene er en eller flere og uavhengig valgt fra halogen, hydroksy, alkyl, haloalkyl og alkoksy; X er valgt fra en binding, -(CRcRd)r-, -NR7(CRcRd)r-, -O(CRcRd)r-, -C(O)NR7-,-C(0)NR7(CRcRd)r- hvor R7 er hydrogen eller substituert eller usubstituert alkyl, Rc og Rd er hydrogen eller alkyl, 'r' er 1, 2, eller 3; Z er -OR6 hvor R6 er valgt fra hydrogen, alkyl eller aryl, eller Z er -NR10R11 hvor R10 og R11 kan være samme eller forskjellige og er uavhengig valgt fra hydrogen, substituert eller usubstituert alkyl, -(CReRd)r-C(O)OH, -(CRcRd)r-C(O)O-alkyl og sykloalkyl eller R10 og R11 sammen kan danne en substituert eller usubstituert, mettet eller umettet 3 til 12 leddet syklisk ring, hvor de umettede sykliske ringen kan ha en eller flere dobbeltbindinger; og 'n' er 1, 2 eller 3;hvor, dersom ikke annet er angitt, refererer begrepet "substituert" som brukt her til en gruppe eller del med en eller flere substituenter festet til strukturskjelettet til gruppen eller delen ; idet slike substituenter er valgt fra: halogen, cyano, alkyl, haloalkyl, aryl, sykloalkyl, heteroaryl, heterosyklisk ring, -C(O)ORx, -C(O)Rx, C(O)NRxRy , -NRxC(O)NRyRz, -N(Rx)S(O)Ry, -N(Rx)S(O)2Ry,-NRxRy, -NRx C(O)Ry, -S(=)2NRxRy, -ORx og− S(O)2Rx; hvor hver opptreden av Rx, Ry og Rz er uavhengig valgt fra hydrogen, halogen, alkyl, haloalkyl, sykloalkyl, og aryl.2. Forbindelsen i henhold til krav 1 som er valgt fra: Metyl 2-fluor-5-((2R, 4R)-2-(((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl) benzoat;Metyl 2-fluor-5-((2R, 4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl-3-((2R, 4S)-2-((((R)-1-(naftalen-1 -yl)etyl)amino)metyl)chroman-4-yl)benzoat;Metyl 2-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl) etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 3-metyl-5(2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 4-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)metyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-etyl-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-etyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)metyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-isopropyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-syklopropyl-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)metyl)amino)-metyl)chroman-4-yl)benzoat;Metyl 2-syklopropyl-5-((2R,4S)-2-((((R)-1-naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2,6-difluor-3-((2R,4R)-2-(((R)-1-(naftalen-1-yl)metyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 4-fluor-2-metyl-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-yl)benzoat;Metyl 4-fluor-2-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) -metyl)chroman-4-yl)benzoat;Metyl 2, 3-dimetyl-5-((2R,4S)-2-((((R)-1 -(naftalen-1 -yl)etyl)amino) -metyl)chroman-4-yl)benzoat;Metyl 5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzoat; Metyl 2-metyl-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-(2R,4S)-2-((((R)-1-(naftalen-1 -yl)etyl)amino)metyl)-chroman-4-yl)benzoate;Metyl 2-fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 3-fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 4-fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-yl)benzoat;Metyl 2-metoksy-5-((2R4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)benzoat;Metyl 2-metoksy-3-((2R,4R)-2-((((R)-2-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl) benzoat;Metyl 2-metoksy-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)benzoat;Metyl 4-metoksy-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)eetyl)amino)-metyl)chroman-4-yl) benzoat;Metyl 2-(2-metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(3-metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(2-fluor-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(2-fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(2-fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-fenoksy)acetat;Metyl 2-(3-fluor-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(3-fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)-chroman-4-yl)fenoksy)acetat; Metyl 2-(4-fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-fenoksy)acetat;Metyl 2-metyl-2-(3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-yl)fenoksy)propanoat;Metyl 4-((2R,4R)-2-((((R)-1-(naftalen-l-yl)etyl)amino)metyl)chroman-4-yl)benzoat;Metyl 4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzoat;Metyl 2-metyl-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl-)chroman-4-yl)benzoat;Metyl 2-metyl-4-((2R,4S)-2-((((R)-1-( naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzoat;Metyl 4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzoat;Metyl 2,6-difluor-4-((2R,4S)-2-((((R)-1-(naftalen-1 -yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 3-metoksy-4-((2R,4R)-2-((((R)-1-(naftalen-1-y)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 3-metoksy-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-benzoat;Metyl 3-fluor-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-fluor-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman -4-yl)benzoat;Metyl 2-(4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)acetat;Metyl 2-(4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)acetat;Metyl 2-(2-fluor-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)fenoksy)acetat; Metyl 2-(2-fluor-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)fenoksy)acetat;Metyl 2-(4-(2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenyl)acetat;Metyl 2-(4-((2R,4S)-2-(((( R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenyl)acetat;Metyl 2-metyl-2-(4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)fenyl)propanoat;Metyl 2-metyl-2-(4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) -metyl)chroman-4-yl)fenyl)propanoat;Metyl 3-metyl-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-yl)benzoat;Metyl 2-fluor-54(2S,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)chroman-4-yl)benzoat;Metyl 3-((2S,4R)-2-((((R)-1-( naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) benzoat;Metyl 2-metyl-5-((2S,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-((2S,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-benzoat;Metyl 2-(4-((2S,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)acetat;Metyl 2-(4-((2S,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)acetat;Metyl 5-((2R,4R)-2-((((R)-1-(4-fluornaftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzoat;Metyl 5-((2 R,4S)-2-((((R)-1-(4-fluornaftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzoat;Metyl 3-((2 R,4R)-2-((((R)-1 -(4-fluornatfalen-1-yl)etyl)amino)metyl)-chroman-4-yI)-2-metoksybenzoat;Metyl 3-((2 R,4S)-2-((((R)-1-(4-fluornaftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)-2-metoksybenzoat;Metyl 4-((2R)-2-NR)-1-(4-fluor-3-metoksyfenyl)etyl)arnino)metyl)chroman-4-yl)-2-metylbenzoat;Metyl 3-((2R)-2-((((R)-1-(4-fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzoat;Metyl 5-((2R)-2-((((R)-1-(4-fluor-3-metoksyphenyl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzoat;Metyl 3-((2R)-2-((((R)-1-(4-fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-5-metylbenzoat;Metyl 3-((2 R)-2-((((R)-1-(4-fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-4-metylbenzoat;Metyl 2-fluor-5-((2S,4R)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)benzoat;Metyl 2-fluor-5-((2R,4S)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-((2S,4R)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-((2R,4S)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)ethyl)-chroman-4-yl)benzoat;Metyl 2-metoksy-3-((2R,4R)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)benzoat;Metyl 5-((2S,4R)-2-(2-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)-2-metylbenzoat;Metyl 5-((2R,4S)-2-(2-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)etyl)-chroman-4-yl)-2-metylbenzoat;Metyl 5-((2S,4R)-2-(((R)-1-(4-fluor-3-metoksyfenyl)etyl)amino)-etyl)chroman-4-yl)-2-metylbenzoat;Metyl 5-((2R,4S)-2-(((R)-1-(4-fluor-3-metoksyfenyl)etyl)amnino)etyl)-chroman-4-yl)-2-metylbenzoat;Metyl 2-fluor-5-((2S,4S)-2-(3-((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzoat;Metyl 2-fluor-5-((2R,4R)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-((2S,4S)-2-(3-(((R)-1-(naftalen-1-ypl)etyl)amino)-propyl)-chroman-4-yl)benzoat;Metyl 2-metyl-5-((2R,4R)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)chroman-4-yl)benzoat;Metyl 5-((2S,4S)-2-(3-(((R)-1-(4-fluor-3-metoksyfenyl)etyl)amino)propyl)chroman-4-yl)-2-metylbenzoate;Metyl 4-((2S,4S)-2-(3-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)-3-metylbenzoat;Metyl 4-((2S,4S)-2-(3-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzoat;Metyl 5-((2S,4S)-2-(3-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)-2-metylbenzoat;2,6-dimetyl-3-((2R,4S)-2-((((R)-1 -(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;2,6-dimetyl-3-((2R,4S)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)-chroman-4-yl) benzosyre hydroklorid;2,6-dimetyl-3-((2R,4R)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzosyre hydroklorid;2,6-dimetyl-3-((2S,4S)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzosyre hydroklorid;3-((2S,4S)-2-(3-(((R)-1-(4-fluor-3-metoksyfenyl)etyl) amino)propyl)-chroman-4-yl)-2,6-dimetylbenzosyre hydroklorid;2-Fluor-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;3-metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;4-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-etyl-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-etyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4yl) benzosyre hydroklorid;2-lsopropyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)-chroman-4-yl)benzosyre hydroklorid;2-Syklopropy1-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;2-Syklopropy1-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)-metyl)-chroman-4-yl)benzosyre hydroklorid;2,6-Difluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;4-Fluor-2-metyl-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;4-Fluor-2-metyl-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;2,3-Dimetyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzosyre hydroklorid;2-Metyl-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-ypl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;3-Fluor-54(2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;4-Fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metoksy-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;2-Metoksy-3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;2-Metoksy-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;4-Metoksy-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) benzosyre hydroklorid;2-(2-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(3-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(2-Fluor-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(2-Fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl) etyl) amino)metyl) chroman-4-yl) fenoksy) eddiksyre hydroklorid;2-(2-Fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(3-Fluor-5-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(3-Fluor-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)ethyl)amino)metyl)-chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(4-Fluor-3-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) fenoksy)eddiksyre hydroklorid;2-Metyl-2-(3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)propionsyre hydroklorid;4-((2R,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;4-((2R,4S)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) benzosyre hydroklorid;4-((2R,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzosyre hydroklorid;4-((2R,4S)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-(trifluormetyl)benzosyre hydroklorid;2,6-Difluor-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;3-Metoksy-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;3-Metoksy-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzosyre hydroklorid;3-Fluor-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Fluor-4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-(4-((2R,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) fenoksy)eddiksyre hydroklorid;2-(4((2R,4S)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)rnetyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(2-Fluor-4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(2-Fluor-4((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenoksy)eddiksyre hydroklorid;2-(4-((2R,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenyl)eddiksyre hydroklorid;2-(4-((2R,4S)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenyl)eddiksyre hydroklorid;2-Metyl-2-(4-((2R,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)fenyl)propionsyre hydroklorid;2-Metyl-2-(4-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl) fenyl) propionsyre hydroklorid;3-Metyl-4-((2R,4S)-2-((((R)-1-(naftalen- 1 -yl)etyl)amino) metyl)chroman-4-yl)benzosyre hydroklorid;2-Fluor-5-((2S,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;3-((2S,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-54(2S,4R)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2S,45)-2-((((R)-1-(naftalen-1-yl)etyl)amino ) metyl)chroman-4-yl)benzosyre hydroklorid;2-(4-((2S,4R)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4yl)fenoksy)eddiksyre hydroklorid;2-(4-((2 S,4S)-2-(((( R)-1 -(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) fenoksy)eddiksyre hydroklorid;4-((2R,4S)-2-((((R)-1-(4-Fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzosyre hydroklorid;3-((2R,4S)-2-((((R)-1-(4-Fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-2-metylbenzosyre hydroklorid;5-((2R,4S)-2-((((R)-1-(4 Fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-2-metyl benzosyre hydroklorid;3-((2R,4S)-2-((((R)-1-(4-Fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-5-metylbenzosyre hydroklorid;3-((2R,4S)-2-((((R)-1-(4-Fluor-3-metoksyfenyl)etyl)amino)metyl)-chroman-4-yl)-4-metylbenzosyre hydroklorid;5-((2R,4R)-2-((((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-metyl benzosyre hydroklorid;5-((2R,4S)-2-((((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-metyl benzosyre hydroklorid;3-((2R,4S)-2-((((R)-1 -(4-Fluornaftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-metoksybenzosyre hydroklorid;3-((2R,4R)-2-((((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)metyl)chroman-4-yl)-2-metoksybenzosyre hydroklorid;2-Fluor-5-((2S,4R)-2-(2-(((R)-1 -(naftalen- 1 -yl) etyl)amino)etyl)-chroman-4-yl) benzosyre hydroklorid;2-Fluor-5-((2R,4S)-2-(2-(((R)-1-(naftalen-1-yl)ethyI)amino)etyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2,4R)-2-(2-(yR)-1-(naftalen-1-ypethyDamino)etyl)chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2R,4S)-2-(2-(((R)-1-(naftalen-1-yl)etyl)amino)etyl)chroman-4-yl) benzosyre hydroklorid;2-Metoksy-3-((2R((R)-1-( naftalen-1-yl)etyl)amino)etyl)chroman-4-yl) benzosyre hydroklorid;5-((2S,4R)-2-(2-(((R)-1-(4-fluornaftalen-1-yl )etyl)amino)etyl)chroma n-4-yl)-2-metyl benzosyre hydroklorid;5-((2R,4S)-2-(2-(((R)-1-(4-fluornaftalen-1-yl)etyl)amino)etyl)chroman-4 yl)-2-metyl benzosyre hydroklorid;5-((2S,4R)-2-(2-(((R)-1-(4-Fluor-3-metoksy fenyl)etyl)amino)etyl)-chroman-4-yl)-2-metylbenzosyre hydroklorid;5-((2R,4S)-2-(2-(((R)-1-(4-Fluor-3-metoksy fenyl)etyl)amino)etyl)-chroman-4-yl)-2-metylbenzosyre hydroklorid;2-Fluor-5-((2S,45)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)chroman-4-yl) benzosyre hydroklorid;2-Fluor-5-((2R,4R)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2S,4S)-2-(3-(((R)-1-(naftalen-1-yl)etyl)amino)propyl)-chroman-4-yl)benzosyre hydroklorid;2-Metyl-5-((2R,4R)-2-(3-(((R)-1-(naftalen-1-ypethypamino)propyl)chroman-4-yl)benzosyre hydroklorid;5-((2S,4S)-2-(3-(((R)-1-(4-Fluor-3-metoksyfenyl)etyl)amino)-propyl)chroman-4-yl)-2-metylbenzosyre hydroklorid;4-((2S,4S)-2-(3-(((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)propyl)chroman-4-yl)-3-metylbenzosyre hydroklorid;4-((2S,4S)-2-(3-(((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)propyl)chroman-4-yl)benzosyre hydroklorid;5-((2S,4S)-2-(3-(((R)-1-(4-Fluornaftalen-1-yl)etyl)amino)propyl)chroman-4-yl)-2-metylbenzosyre hydroklorid;Metyl 2-(3-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) benzamido)acetat;Metyl 2-(2-metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl) benzamido) acetat;2-(3-((2R,4S)-2-((((R)-1-(Naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)benzamido) eddiksyre hydroklorid;2-(2-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl) benzamido) eddiksyre hydroklorid;N,2-Dimetyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl) benzamid hydroklorid;N, N,2-Trimetyl-5-((2R,4S)-2-((((R)-1 -(naftalen-1-yl)etyl)amino)metyl)-chroman-4-yl)benzamid hydroklorid;2-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4yl)benzamid hydroklorid;N-Etyl-N,2-dimetyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl) chroman-4-yl)benzamid hydroklorid;N,N-Dietyl-2-metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino) metyl)chroman-4-yl)benzamid hydroklorid; og(2-Metyl-5-((2R,4S)-2-((((R)-1-(naftalen-1-yl)etyl)amino)metyl)chroman-4-yl)fenyl)(pyrrolidin-1-yl)metanon hydroklorid;eller et farmasøytisk akseptabelt salt derav.3. En farmasøytisk sammensetning innbefattende en eller flere forbindelser av formel (V) i henhold til krav 1, og en eller flere farmasøytisk akseptable eksipienter.4. Forbindelse i henhold til krav 1 eller et farmasøytisk akseptabelt salt derav for behandling, håndtering og/eller avlastning av en sykdom eller lidelse, syndrom eller tilstand valgt fra hyperparathyoridisme, kronisk nyrefeil (med eller uten dialyse), kronisk leverlidelse (med eller uten dialyse) og deres komplikasjoner; parathyorid adenom, parathyroid hyperplasi, parathyroid karsinom, vaskulær og valvulær forkalkning, abnormal kalsium homeostase, hyperkalsemi, abnormal fosfor homeostase, hypofosfatemi, benrelaterte lidelse og komplikasjoner som stammer fra hyperparathyroidisme, kronisk leverlidelse eller parathyroid karsinom, bentap etter nyretransplantasjon, osteotitt fibrosa cystika, adynamisk benlidelse, renal benlidelse, kardiovaskulære komplikasjoner som stammer fra hyperthyroidisme eller kronisk leverlidelse, visse ondartetheter hvor (Ca2+)e ionene er abnormalt høye, hjerte, nyre eller innvollsdysfunksjoner, podocytt-relaterte lidelser, abnormal innvollsmotilitet, diaré, forhøyet gastrin eller magesyresekresjon for direkte eller indirekte hjelp ved atrofisk gastritt eller forbedre absorpsjonen av farmakologiske forbindelser, legemidler eller tilskudd fra mage-tarmkanalen ved økning av gastrisk surhet.5. Forbindelse for anvendelse i henhold til krav 4, hvor hyperparathyroidisme er primær hyperparathyroidisme, sekundær hyperparathyroidisme eller tertiær hyperparathyroidisme.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Lupin Limited
Kalpataru Inspire 3rd Floor Off Western Express Highway Santacruz (East) Mumbai 400 055 IN

Oppfinner(e) info chevron_right

SHUKLA, Manojkumar, Ramprasad
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
SARDE, Ankush, Gangaram
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
LORIYA, Rajeshkumar, Maganlal
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
PACHPUTE, Vipul, Dilip
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
WALKE, Navnath, Bajirao
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
KHAN, Talha, Hussain
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
KULKARNI, Sanjeev, Anant
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN
PALLE, Venkata, P.
Lupin Limited (Research Park)46A /47ANande VillageTaluka Mulshi Pune 412 115 IN
KAMBOJ, Rajender, Kumar
Lupin Limited (Research Park)46A / 47ANande VillageTaluka Mulshi Pune 412 115 IN

Fullmektig info chevron_right

Fullmektig i Norge:
BRYN AARFLOT AS
Stortingsgata 8 0161 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 979993269
Din referanse: P5883NO00-BGC
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
HGF Limited
1 City Walk Leeds LS11 9DX GB

Prioritet info chevron_right

2012.02.24, IN KO01782012

2012.09.07, IN KO10302012

Anførte dokumenter info chevron_right

LIONEL KIEFER ET AL: "Design and synthesis of cyclic sulfonamides and sulfamates as new calcium sensing receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 24, 2 October 2010 (2010-10-02), pages 7483-7487, XP028129144, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.10.006 [retrieved on 2010-10-10] (B1)

WO-A1-2012/127388 (B1)

Lionel Kiefer ET AL: "Novel calcium sensing receptor ligands: a patent survey", Expert Opin. Ther. Patents, 1 January 2011 (2011-01-01), pages 681-698, XP055062103, DOI: 10.1517/13543776.2011.568479 Retrieved from the Internet: URL:http://informahealthcare.com/doi/pdf/1 0.1517/13543776.2011.568479 [retrieved on 2013-05-07] (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
05-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Varsel om betaling av første årsavgift (3319) (PTEP2817299)
04-01 Via Altinn-sending EP Varsel om betaling av første årsavgift (3319) (PTEP2817299)
Utgående EP Registreringsbrev (3210) (PTEP2817299)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP2817299)
Innkommende, AR335040125 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP oversettelse
01-03 EP oversettelse EP krav
01-04 Fullmakt Fullmakt
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Neste fornyelse/årsavgift:

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 13. avg. år (EP) 2025.02.12 5460 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 12. avg. år (EP) 2024.02.05 3850 Murgitroyd & Company Limited Betalt og godkjent
Årsavgift 11. avg. år (EP) 2023.02.08 3500 CPA GLOBAL LIMITED Betalt og godkjent
Forsinkelsesavgift patent 2022.03.04 700 The International Renewals Group Betalt og godkjent
Årsavgift 10. avg. år (EP) 2022.03.04 3200 The International Renewals Group Betalt og godkjent
Årsavgift 9. avg. år (EP) 2021.02.12 2850 PROTECTOR IP AS Betalt og godkjent
Årsavgift 8. avg. år (EP) 2020.03.02 2550 PROTECTOR IP AS Betalt og godkjent
31915014 expand_more 2019.09.09 5580 PROTECTOR IP AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 28.05.2025 07:16:27